DCB F1

Drug Profile

DCB F1

Alternative Names: DCB-F1

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Development Center for Biotechnology
  • Class
  • Mechanism of Action Interferon alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 20 Jan 2016 DCB F1 is available for licensing as of 20 Jan 2016. http://www.dcb.org.tw/dcbe.aspx?pg=en-rd-pipeline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top